30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
The project Aging in Place applies a novel approach to investigate how social care services in Sweden are adapted to preferences and needs of older persons living at home with dementia (including their partners). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A persistent gap remains between policy ambitions and everyday practice. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This intervention represents the output of the iterative development of a complex intervention to fulfil an unmet need for PwD and sensory loss. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Differentially methylated positions (DMPs) between persons with and without late-onset Alzheimer's disease (LOAD) were observed at 477 of 769,190 loci in a plurality of genes. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The pathological potential of human astroglia in Alzheimer's disease (AD) was analysed in vitro using induced pluripotent stem cell (iPSC) technology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We found that brain YKL-40 immunoreactivity was observed in a subset of astrocytes in all four diseases and in controls. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In regards to policy-making decisions and resource allocation, the success of making technology more accessible to the marginalized older population should not be measured solely on the outcome of avoiding acute care services; its benefits should rather be assessed with functional health as the focus of intervention, including measures of psychophysical well-being and life satisfaction.9 Higher-end immersive technologies could be installed as a private expense in a patient's room; they could also be made available in common recreational areas within a leisure and/or fitness room, provided by the LTC facility through support of government subsidies and incentives aimed at promoting health of its aging population. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hearing loss affects close to 1.3 billion people and is a growing global health concern as the fourth leading contributor to years lived with disability. 1 The global economic cost associated with hearing loss is estimated at 750 billion United States dollars (US$) annually.2 However, hearing loss has limited public health support, especially in low-and middle-income countries, where incidence is high and resources often scarce and unequally distributed.
Evidence: low
Full summary, score breakdown and related studies → Original source
An aging population and human longevity is a global trend. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The system uses a collected dataset of 1928 records, taken from 11 HD patients and 11 healthy persons in Lithuania, to gather statistics about examinations and presents the results as medical evaluation with prediction on the state of health. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Family carers encounter several challenges related to caring for people with dementia, and they need support in managing care recipients’ health needs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic activation of brain innate immunity is a prominent feature of Alzheimer’s disease (AD) and primary tauopathies. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
PLCG2 expression is restricted primarily to microglia and granule cells of the dentate gyrus. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Volga German kindreds are a group of seven related families with autosomal dominant early-onset Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hundreds of proteins are known to be citrullinated and hypercitrullination is associated with autoimmune diseases including rheumatoid arthritis (RA), lupus, ulcerative colitis (UC), Alzheimer's disease, multiple sclerosis (MS), and certain cancers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In BriefIn the search for biomarkers of synapse loss associated with Alzheimer's disease (AD), we used shotgun proteomics to identify a panel of 9 synaptic proteins detectable in human cerebrospinal fluid (CSF).Expression at the human synapse was verified using super resolution microscopy. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
We devise a conceptually different computational framework based on a holistic view, where single-cell datasets are used to infer global, large-scale regulatory networks. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Failure to translate successful neuroprotective preclinical data to a clinical setting in Alzheimer's disease (AD) indicates that amyloidopathy and tauopathy alone provide an incomplete view of disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Approximately half of older people report sleep disturbances, which are associated with various health conditions, including neurodegenerative disease and dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The results of the aducanumab studies have not been published in peer-reviewed form and both the analysis presented by Dr Knopman and collaborators and this perspective are based on data presented in 2019 at the Clinical Trials in AD (CTAD) meeting3; both discussions must be seen as tentative until full data are available. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Neuronal insulin resistance is a significant feature of Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Growing evidence suggests that agonists of glucagon-like peptide (GLP-1) receptor exert neuroprotective and neurorestorative effects across a range of experimental models of neuronal degeneration, and, recently, a pilot clinical trial of Liraglutide in Alzheimer’s disease patients showed improvements in cerebral glucose consumption that signifies disease progression. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alogliptin treatment alleviated LPS-induced cognitive impairment as assessed by Morris water maze and novel object recognition tests. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In MCI/AD, both the CSF and serum samples had significantly elevated mean levels of C-peptide and an incretin, and reduced expression of Visfatin, whereas only CSF showed significant reductions in insulin and leptin and only serum had increased glucagon, PAI-1, and ghrelin. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our results demonstrate that DA5‐CH has neuroprotective effects in the STZ‐induced animal model and that DA5‐CH has potential to treat neurodegenerative disorders such as AD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events